Drug Profile
Research programme: COVID-19 DNA vaccines - Entos Pharmaceuticals
Alternative Names: Covigenix candidates - Entos Pharmaceuticals; Pan-coronavirus Fusogenix DNA vaccines (Covigenix) - Entos PharmaceuticalsLatest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator Entos Pharmaceuticals
- Class COVID-19 vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 23 Oct 2020 Entos Pharmaceuticals in collaboration with Clinical Trials Research Center and Canadian Centre for Vaccinology plans a phase I trial for COVID-2019 infections (Prevention) in Canada (Parenteral)
- 23 Oct 2020 Entos Pharmaceuticals plans phase II and phase III trials in COVID-2019 infections (Prevention) (Parenteral) (subject to government and investor funding)
- 30 Jun 2020 Research programme: COVID-19 DNA vaccines is available for licensing as of 30 Jun 2020. https://www.entospharma.com/fusogenix